Carcinoma  >>  Conmana (icotinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Conmana (icotinib) / Betta Pharma
MINT, NCT01514877: Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
20
RoW
Icotinib
Zhejiang Cancer Hospital
Lung Cancer, Metastatic Cancer
07/14
07/14
NCT02726568: High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Recruiting
2
30
RoW
Icotinib, SRS
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Brain Metastases
12/21
12/22
NCT02820116: The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Recruiting
2
67
RoW
Icotinib, Conmana
Beijing Haidian Hospital, Peking University People's Hospital, 307 Hospital of PLA, 309th Hospital of Chinese People's Liberation Army
Non-small Cell Lung Cancer(NSCLC)
04/23
04/23
NCT01534585: Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Completed
1/2
48
RoW
Icotinib, Conmana, intensity-modulated radiotherapy, IMRT, Paclitaxel and Cisplatin, Quality of life, QoL, Epidermal growth factor receptor status, EGFR
Taizhou Hospital
Nasopharyngeal Carcinoma
02/13
02/15
NCT01516983: Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Checkmark CMSTO 2014
Nov 2014 - Nov 2014: CMSTO 2014
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1/2
15
RoW
icotinib, BPI-2009, Conmana, Whole brain radiotherapy, RT, XRT, Radiotherapy, WBRT
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Brain Metastases
06/13
12/13

Download Options